CLN3

CLN3 Full Name

ceroid-lipofuscinosis, neuronal 3

CLN3 Introduction

CLN3, also designated as battenin, is a multi-pass transmembrane protein encoded by the CLN3 gene on chromosome 16p12.1. Mutations in CLN3 are the causative genetic lesion underlying juvenile neuronal ceroid lipofuscinosis (JNCL), also known as Batten disease — the most common form of the neuronal ceroid lipofuscinoses (NCLs), a group of fatal inherited neurodegenerative disorders characterized by the progressive accumulation of autofluorescent storage material in lysosomes. CLN3 localizes predominantly to the late endosomal/lysosomal compartment, although it has also been detected in the Golgi apparatus, lipid rafts, and synaptic vesicles.

Figure 1. The CLN3 gene and protein functions in cellular trafficking

Lysosomal Function and Cellular Homeostasis
CLN3 is a multipass transmembrane protein that primarily resides in the late endosomal/lysosomal membrane and participates in the regulation of lysosomal pH, vesicular trafficking, and autophagy. Loss of functional CLN3 results in lysosomal alkalinization, impaired autophagosome-lysosome fusion, and defective clearance of autophagic substrates. Additionally, CLN3 has been implicated in the post-Golgi trafficking of lysosomal hydrolases — CLN3-deficient cells exhibit mis-sorting of cathepsin D and other lysosomal enzymes, contributing to the accumulation of undigested substrates. CLN3 also modulates the endocytic recycling of synaptic vesicle proteins, providing a mechanistic link between CLN3 dysfunction and the pronounced synaptic pathology observed in Batten disease.

Batten Disease Pathogenesis and Emerging Therapeutic Strategies
Batten disease (JNCL) typically manifests in early childhood (4-10 years of age) with progressive vision loss due to retinal degeneration, followed by cognitive decline, seizures, motor deterioration, and premature death by the third decade of life. The most common disease-causing mutation is a 1.02 kb intragenic deletion spanning exons 7 and 8, resulting in a truncated, non-functional protein. Current therapeutic approaches under investigation include: (i) gene therapy using AAV vectors to deliver functional CLN3 cDNA, which has shown efficacy in preclinical mouse models; (ii) small-molecule read-through agents to bypass nonsense mutations; (iii) enzyme replacement therapy targeting lysosomal storage; and (iv) antisense oligonucleotides for splice correction. The development of blood-based biomarkers for early diagnosis and treatment monitoring remains a high-priority research direction.

Alternate Names for CLN3

ceroid-lipofuscinosis, neuronal 3; Batten, Spielmeyer-Vogt disease; BTS; MGC102840; JNCL; battenin; Batten disease protein; OTTHUMP00000122517

• 1.Gilani N, Razmara E, Ozaslan M, et al. A novel deletion variant in CLN3 with highly variable expressivity is responsible for juvenile neuronal ceroid lipofuscinoses. Acta Neurologica Belgica, 2021, 121(3): 737-748.